301089 拓新药业
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-1.962-1.26016.31623.1668.275
总资产报酬率 ROA (%)-1.750-1.10613.20217.7045.616
投入资产回报率 ROIC (%)-1.910-1.22215.15020.5366.490

边际利润分析
销售毛利率 (%)29.36129.86757.87660.11437.915
营业利润率 (%)-13.389-5.62438.50241.96315.771
息税前利润/营业总收入 (%)-13.469-7.38837.48341.08017.231
净利润/营业总收入 (%)-11.107-4.71529.09336.51413.077

收益指标分析
经营活动净收益/利润总额(%)103.58482.829100.57397.55399.308
价值变动净收益/利润总额(%)-9.072-5.6002.2481.7750.806
营业外收支净额/利润总额(%)0.41514.475-1.627-1.236-1.542

偿债能力分析
流动比率 (X)4.6864.0954.2272.3923.129
速动比率 (X)3.2163.0133.1771.8232.473
资产负债率 (%)9.88611.70112.81825.32921.264
带息债务/全部投入资本 (%)0.1890.2080.7538.5508.033
股东权益/带息债务 (%)51,641.80646,823.94112,857.6911,037.2261,102.903
股东权益/负债合计 (%)911.558754.662680.152294.798370.289
利息保障倍数 (X)554.7239.108-93.138-110.78910.137

营运能力分析
应收账款周转天数 (天)77.95898.28941.73522.81433.946
存货周转天数 (天)260.168233.101227.715234.763188.665